(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 August 2009 (27.08.2009)

PCT

(10) International Publication Number
WO 2009/103969 A8

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/GB2009/000443

(22) International Filing Date:
18 February 2009 (18.02.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0802931.6 18 February 2008 (18.02.2008) GB

(71) Applicant *(for all designated States except US)*: **QUEEN MARY & WESTFIELD COLLEGE** [GB/GB]; Mile End Road, London E1 4NS (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **VINSON, Gavin Paul** [GB/GB]; School of Biological and Chemical Sciences, Queen Mary, University of London, Mile End Road, London, E1 4NS (GB). **BARKER, Stewart** [GB/GB]; School of Biological and Chemical Sciences, Queen Mary, University of London, Mile End Road, London, E1 4NS (GB). **PUDDEFOOT, John, Richard** [GB/GB]; School of Biological and Chemical Sciences, Queen Mary, University of London, Mile End Road, London, E1 4NS (GB).

(74) Agents: **BRAMLEY, Sarah, Jane** et al.; Kilburn & Strode LLP, 20 Red Lion Street, London WC1R 4PJ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with amended claims (Art. 19(1))*

(48) Date of publication of this corrected version:
14 January 2010

(15) Information about Correction:
see Notice of 14 January 2010

(54) Title: SYNTHETIC SCFV ANALOGUE TO THE 6313/G2 (ANTI ANGIOTENSIN II TYPE 1 RECEPTOR) MONOCLONAL ANTIBODY VARIABLE REGIONS

(57) Abstract: The present invention provides a specific binding molecule which specifically binds to a peptide having the amino acid sequence of EDGIKRIQDD and comprises a polypeptide having an immunoglobulin VL domain linked to an immunoglobulin VH domain in which the VL domain comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2 and VLCDR3, and in which the VH domain comprises Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2, VHCDR3, each having a respective amino acid sequence as follows in which VHCDR1 is GYSFTGYNMN VHCDR2 is NIDPYYGGTTYNQKFKG VHCDR3 is EVDY VLCDR1 is RASKSVSTSTSGYSYMH VLCDR2 is LVSNLES VLCDR3 is QHIRELTRSEG or an amino acid sequence at least 70% identical thereto.

WO 2009/103969 A8